News and Announcements
Prescient Therapeutics Investor Presentation April 2016
- Published April 13, 2016 11:52AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
13th April 2016, ASX Announcement
Investment Summary: Why all the excitement about AML?
- Acute Myeloid Leukemia (AML) is an area of substantial unmet medical need.
– One of the worst survival rates of all cancers
– Standard of care unchanged for 40 years - A disease of intense interest for clinicans, pharma companies and investors
- Celator Pharmaceuticals (NASDAQ: CPXX) showed what can happen when enhancing the standard of care in AML
– Market cap recently surged from small cap to $780M
-Dr Jeff Lancet was the Principal Investigator on CPXX’s ground-breaking trial - PTX has successful Phase 1 trial in AML (conducted at Moffitt and MD Anderson)
To view the full article please click on the button below.